Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35


Peak expiratory flow as an endpoint for clinical trials in asthma: a comparison with FEV1.

Halpin DMG, Meltzer EO, Pisternick-Ruf W, Moroni-Zentgraf P, Engel M, Zaremba-Pechmann L, Casale T, FitzGerald JM.

Respir Res. 2019 Jul 18;20(1):159. doi: 10.1186/s12931-019-1119-6.


Tiotropium add-on therapy is safe and reduces seasonal worsening in paediatric asthma patients.

Vogelberg C, Szefler SJ, Vrijlandt EJLE, Boner AL, Engel M, El Azzi G, Vulcu SD, Moroni-Zentgraf PM, Eickmeier O, Hamelmann EH.

Eur Respir J. 2019 Jun 13;53(6). pii: 1801824. doi: 10.1183/13993003.01824-2018. Print 2019 Jun.


Inhalation Devices.

Moroni-Zentgraf P, Usmani OS, Halpin DMG.

Can Respir J. 2018 Sep 18;2018:5642074. doi: 10.1155/2018/5642074. eCollection 2018. No abstract available.


Pharmacokinetics of tiotropium in asthmatic children aged 6-11 years support its safety profile.

Sharma A, Aalbers R, Hamelmann E, Goldstein S, Engel M, Moroni-Zentgraf P, Vogelberg C.

Pediatr Allergy Immunol. 2018 Nov;29(7):773-776. doi: 10.1111/pai.12952. Epub 2018 Sep 3. No abstract available.


Tiotropium add-on therapy improves lung function in children with symptomatic moderate asthma.

Vogelberg C, Engel M, Laki I, Bernstein JA, Schmidt O, El Azzi G, Moroni-Zentgraf P, Sigmund R, Hamelmann E.

J Allergy Clin Immunol Pract. 2018 Nov - Dec;6(6):2160-2162.e9. doi: 10.1016/j.jaip.2018.04.032. Epub 2018 May 8. No abstract available.


Efficacy of tiotropium in adults with moderate asthma, by leukotriene receptor antagonist use at baseline.

Hashimoto S, Casale TB, Engel M, Moroni-Zentgraf P, Bour LJ, Kerstjens HAM.

Allergol Int. 2018 Jul;67(3):411-413. doi: 10.1016/j.alit.2017.12.002. Epub 2018 Feb 15. No abstract available.


Safety and efficacy of tiotropium in children aged 1-5 years with persistent asthmatic symptoms: a randomised, double-blind, placebo-controlled trial.

Vrijlandt EJLE, El Azzi G, Vandewalker M, Rupp N, Harper T, Graham L, Szefler SJ, Moroni-Zentgraf P, Sharma A, Vulcu SD, Sigmund R, Chawes B, Engel M, Bisgaard H.

Lancet Respir Med. 2018 Feb;6(2):127-137. doi: 10.1016/S2213-2600(18)30012-2. Epub 2018 Jan 18.


Tiotropium Respimat Add-on Is Efficacious in Symptomatic Asthma, Independent of T2 Phenotype.

Casale TB, Bateman ED, Vandewalker M, Virchow JC, Schmidt H, Engel M, Moroni-Zentgraf P, Kerstjens HAM.

J Allergy Clin Immunol Pract. 2018 May - Jun;6(3):923-935.e9. doi: 10.1016/j.jaip.2017.08.037. Epub 2017 Nov 22.


A phase III randomized controlled trial of tiotropium add-on therapy in children with severe symptomatic asthma.

Szefler SJ, Murphy K, Harper T 3rd, Boner A, Laki I, Engel M, El Azzi G, Moroni-Zentgraf P, Finnigan H, Hamelmann E.

J Allergy Clin Immunol. 2017 Nov;140(5):1277-1287. doi: 10.1016/j.jaci.2017.01.014. Epub 2017 Feb 9.


Pharmacokinetics of tiotropium administered by Respimat® in asthma patients: Analysis of pooled data from Phase II and III clinical trials.

Sharma A, Kerstjens HA, Aalbers R, Moroni-Zentgraf P, Weber B, Dahl R.

Pulm Pharmacol Ther. 2017 Feb;42:25-32. doi: 10.1016/j.pupt.2016.12.003. Epub 2016 Dec 28.


A randomised controlled trial of tiotropium in adolescents with severe symptomatic asthma.

Hamelmann E, Bernstein JA, Vandewalker M, Moroni-Zentgraf P, Verri D, Unseld A, Engel M, Boner AL.

Eur Respir J. 2017 Jan 11;49(1). pii: 1601100. doi: 10.1183/13993003.01100-2016. Print 2017 Jan.


Safety and tolerability of once-daily tiotropium Respimat(®) as add-on to at least inhaled corticosteroids in adult patients with symptomatic asthma: A pooled safety analysis.

Dahl R, Engel M, Dusser D, Halpin D, Kerstjens HAM, Zaremba-Pechmann L, Moroni-Zentgraf P, Busse WW, Bateman ED.

Respir Med. 2016 Sep;118:102-111. doi: 10.1016/j.rmed.2016.07.001. Epub 2016 Jul 2.


Tiotropium improves lung function, exacerbation rate, and asthma control, independent of baseline characteristics including age, degree of airway obstruction, and allergic status.

Kerstjens HA, Moroni-Zentgraf P, Tashkin DP, Dahl R, Paggiaro P, Vandewalker M, Schmidt H, Engel M, Bateman ED.

Respir Med. 2016 Aug;117:198-206. doi: 10.1016/j.rmed.2016.06.013. Epub 2016 Jun 14.


Tiotropium add-on therapy in adolescents with moderate asthma: A 1-year randomized controlled trial.

Hamelmann E, Bateman ED, Vogelberg C, Szefler SJ, Vandewalker M, Moroni-Zentgraf P, Avis M, Unseld A, Engel M, Boner AL.

J Allergy Clin Immunol. 2016 Aug;138(2):441-450.e8. doi: 10.1016/j.jaci.2016.01.011. Epub 2016 Mar 5.


Pharmacodynamics and Pharmacokinetics Following Once-Daily and Twice-Daily Dosing of Tiotropium Respimat® in Asthma Using Standardized Sample-Contamination Avoidance.

Beeh KM, Kirsten AM, Dusser D, Sharma A, Cornelissen P, Sigmund R, Moroni-Zentgraf P, Dahl R.

J Aerosol Med Pulm Drug Deliv. 2016 Oct;29(5):406-415. Epub 2016 Feb 9.


Tiotropium add-on therapy in patients with uncontrolled asthma.

Kerstjens HA, Moroni-Zentgraf P.

Int J Tuberc Lung Dis. 2015 Dec;19(12):1553. doi: 10.5588/ijtld.15.0409. No abstract available.


The Effect of Tiotropium in Symptomatic Asthma Despite Low- to Medium-Dose Inhaled Corticosteroids: A Randomized Controlled Trial.

Paggiaro P, Halpin DM, Buhl R, Engel M, Zubek VB, Blahova Z, Moroni-Zentgraf P, Pizzichini E.

J Allergy Clin Immunol Pract. 2016 Jan-Feb;4(1):104-13.e2. doi: 10.1016/j.jaip.2015.08.017. Epub 2015 Nov 7.


Erratum to: A randomised dose-ranging study of tiotropium Respimat® in children with symptomatic asthma despite inhaled corticosteroids.

Vogelberg C, Moroni-Zentgraf P, Leonaviciute-Klimantaviciene M, Sigmund R, Hamelmann E, Engel M, Szefler S.

Respir Res. 2015 Oct 20;16:128. doi: 10.1186/s12931-015-0290-7. No abstract available.


Bronchodilator reversibility and cardiac considerations with use of tiotropium.

Kerstjens HA, Moroni-Zentgraf P.

Lancet Respir Med. 2015 Aug;3(8):e25-6. doi: 10.1016/S2213-2600(15)00257-X. No abstract available.


In Vitro Determination of Respimat® Dose Delivery in Children: An Evaluation Based on Inhalation Flow Profiles and Mouth-Throat Models.

Bickmann D, Kamin W, Sharma A, Wachtel H, Moroni-Zentgraf P, Zielen S.

J Aerosol Med Pulm Drug Deliv. 2016 Feb;29(1):76-85. doi: 10.1089/jamp.2014.1166. Epub 2015 Jun 22.


Tiotropium in asthma - Authors' reply.

Kerstjens HA, Moroni-Zentgraf P, Bateman ED.

Lancet Respir Med. 2015 May;3(5):e17. doi: 10.1016/S2213-2600(15)00105-8. No abstract available.


Magnitude of effect of asthma treatments on Asthma Quality of Life Questionnaire and Asthma Control Questionnaire scores: Systematic review and network meta-analysis.

Bateman ED, Esser D, Chirila C, Fernandez M, Fowler A, Moroni-Zentgraf P, FitzGerald JM.

J Allergy Clin Immunol. 2015 Oct;136(4):914-22. doi: 10.1016/j.jaci.2015.03.023. Epub 2015 May 1. Review.


Long-Term Once-Daily Tiotropium Respimat® Is Well Tolerated and Maintains Efficacy over 52 Weeks in Patients with Symptomatic Asthma in Japan: A Randomised, Placebo-Controlled Study.

Ohta K, Ichinose M, Tohda Y, Engel M, Moroni-Zentgraf P, Kunimitsu S, Sakamoto W, Adachi M.

PLoS One. 2015 Apr 20;10(4):e0124109. doi: 10.1371/journal.pone.0124109. eCollection 2015.


A randomised dose-ranging study of tiotropium Respimat® in children with symptomatic asthma despite inhaled corticosteroids.

Vogelberg C, Moroni-Zentgraf P, Leonaviciute-Klimantaviciene M, Sigmund R, Hamelmann E, Engel M, Szefler S.

Respir Res. 2015 Feb 7;16:20. doi: 10.1186/s12931-015-0175-9. Erratum in: Respir Res. 2015;16:128.


A Handling Study to Assess Use of the Respimat(®) Soft Mist™ Inhaler in Children Under 5 Years Old.

Kamin W, Frank M, Kattenbeck S, Moroni-Zentgraf P, Wachtel H, Zielen S.

J Aerosol Med Pulm Drug Deliv. 2015 Oct;28(5):372-81. doi: 10.1089/jamp.2014.1159. Epub 2015 Apr 6.


Tiotropium Respimat in cystic fibrosis: Phase 3 and Pooled phase 2/3 randomized trials.

Ratjen F, Koker P, Geller DE, Langellier-Cocteaux B, Le Maulf F, Kattenbeck S, Moroni-Zentgraf P, Elborn JS; Tiotropium Cystic Fibrosis Study Group.

J Cyst Fibros. 2015 Sep;14(5):608-14. doi: 10.1016/j.jcf.2015.03.004. Epub 2015 Mar 26.


Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomised trials.

Kerstjens HA, Casale TB, Bleecker ER, Meltzer EO, Pizzichini E, Schmidt O, Engel M, Bour L, Verkleij CB, Moroni-Zentgraf P, Bateman ED.

Lancet Respir Med. 2015 May;3(5):367-76. doi: 10.1016/S2213-2600(15)00031-4. Epub 2015 Feb 12.


Once-daily tiotropium Respimat(®) 5 μg is an efficacious 24-h bronchodilator in adults with symptomatic asthma.

Timmer W, Moroni-Zentgraf P, Cornelissen P, Unseld A, Pizzichini E, Buhl R.

Respir Med. 2015 Mar;109(3):329-38. doi: 10.1016/j.rmed.2014.12.005. Epub 2014 Dec 27.


Safety, tolerability, and plasma exposure of tiotropium Respimat® in children and adults with cystic fibrosis.

Konstan MW, Sharma A, Moroni-Zentgraf P, Wang F, Koker P.

J Aerosol Med Pulm Drug Deliv. 2015 Apr;28(2):137-44. doi: 10.1089/jamp.2013.1115. Epub 2014 Nov 7.


Testing two different doses of tiotropium Respimat® in cystic fibrosis: phase 2 randomized trial results.

Bradley JM, Koker P, Deng Q, Moroni-Zentgraf P, Ratjen F, Geller DE, Elborn JS; Tiotropium Cystic Fibrosis Study Group.

PLoS One. 2014 Sep 4;9(9):e106195. doi: 10.1371/journal.pone.0106195. eCollection 2014.


Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis.

Sharma A, Geller DE, Moroni-Zentgraf P, Kattenbeck S, Schmid M, Boland K, Rapp B, Konstan MW, Ratjen F, Elborn JS, Koker P.

Pulm Pharmacol Ther. 2014 Dec;29(2):217-23. doi: 10.1016/j.pupt.2014.08.004. Epub 2014 Aug 24.


Tiotropium in asthmatic adolescents symptomatic despite inhaled corticosteroids: a randomised dose-ranging study.

Vogelberg C, Engel M, Moroni-Zentgraf P, Leonaviciute-Klimantaviciene M, Sigmund R, Downie J, Nething K, Vevere V, Vandewalker M.

Respir Med. 2014 Sep;108(9):1268-76. doi: 10.1016/j.rmed.2014.06.011. Epub 2014 Jul 17.


Tiotropium Respimat® in asthma: a double-blind, randomised, dose-ranging study in adult patients with moderate asthma.

Beeh KM, Moroni-Zentgraf P, Ablinger O, Hollaenderova Z, Unseld A, Engel M, Korn S.

Respir Res. 2014 Jun 3;15:61. doi: 10.1186/1465-9921-15-61.


Safety and efficacy of the once-daily anticholinergic BEA2180 compared with tiotropium in patients with COPD.

Abrahams R, Moroni-Zentgraf P, Ramsdell J, Schmidt H, Joseph E, Karpel J.

Respir Med. 2013 Jun;107(6):854-62. doi: 10.1016/j.rmed.2013.02.005. Epub 2013 Mar 13.


Tiotropium in asthma poorly controlled with standard combination therapy.

Kerstjens HA, Engel M, Dahl R, Paggiaro P, Beck E, Vandewalker M, Sigmund R, Seibold W, Moroni-Zentgraf P, Bateman ED.

N Engl J Med. 2012 Sep 27;367(13):1198-207. Epub 2012 Sep 2.

Supplemental Content

Loading ...
Support Center